PHM De Mulder, C Seynaeve, JB … - Annals of internal …, 1990 - Am Coll Physicians Add to CiteULike Add to Complore Add to Connotea Add to Del.icio.us Add to Digg Add to Facebook
Add to Reddit Add to Technorati Add to Twitter What's this? ... Objective: To compare the efficacy
and side effects of ondansetron with those of high-dose metoclopramide in treating acute ... Cited by 157 - Related articles - All 3 versions
M Marty, P Pouillart, S Scholl, JP Droz, M … - New England Journal …, 1990 - content.nejm.org To compare ondansetron (GR 38032F), a 5-hydroxytryptamine3-receptor antagonist, with metoclopramide
in the prophylaxis of acute cisplatin-induced emesis, we conducted a double-blind crossover
study in 97 patients scheduled to receive cisplatin (80 to 100 mg per square meter of ... Cited by 243 - Related articles - All 5 versions
- ►ascopubs.org [PDF] J Hainsworth, W Harvey, K Pendergrass, B … - Journal of Clinical …, 1991 - jco.ascopubs.org C ISPLATIN is a widely used chemotherapeu- tic agent that produces emesis in virtually all patients
not treated with an adequate antiemetic regimen.! Patients who receive cisplatin at a dose of
100 mg/m 2 have a minimum of five and a median of more than 10 emetic episodes within ... Cited by 93 - Related articles - All 7 versions
- ►ascopubs.org [PDF] F Roila, M Tonato, F Cognetti, E Cortesi, G … - Journal of Clinical …, 1991 - jco.ascopubs.org Ondansetron (OND) is a new 5-HT3 receptor antago- nist that gives complete protection from
emesis/ nausea in approximately 50% of cisplatin (CDDP)- treated patients. To evaluate if dexamethasone
(DEX) added to OND increases antiemetic efficacy, we car- ried out a double-blind ... Cited by 184 - Related articles - All 7 versions
- ►nih.gov [PDF] JF Smyth, RE Coleman, M Nicolson, WM Gallmeier, … - British Medical Journal, 1991 - bmj.com Page 1. doi:10.1136/bmj.303.6815.1423 1991;303;1423-1426 BMJ Cornbleet, SG
Allan, BK Upadhyaya and U Bruntsch JF Smyth, RE Coleman, M Nicolson, WM
Gallmeier, RC Leonard, MA ondansetron? acute cisplatin induced ... Cited by 89 - Related articles - All 5 versions
- ►jcojournal.org [PDF] MG Kris, RJ Gralla, LB Tyson, RA Clark, C … - Journal of Clinical …, 1989 - jcojournal.org DELAYED EMESIS is a distinct syndrome that occurs 24 or more hours following the administration
of the anticancer drug cisplatin.' In a prior study, delayed vomiting occurred in 74% of patients
and delayed nausea in 87% over a four-day period following cisplatin administered at a ... Cited by 179 - Related articles - All 6 versions
F Roila, E Boschetti, M Tonato, C Basurto, S … - American Journal of …, 1991 - journals.lww.com 240 F. ROILA ET AL. FIG. 1. Complete protection (%) from nausea at first cycle by day (numbers
on columns are évaluable patients). ■, Placebo; S3, DEX; Ж, MTC. 0/5). Compliance of patients
was good, with 98% of patients taking all scheduled tablets and 100% of pa- tients ... Cited by 65 - Related articles - All 2 versions
- ►ascopubs.org [PDF] MG Kris, RJ Gralla, RA Clark, LB Tyson, JP O' … - Journal of Clinical …, 1985 - jco.ascopubs.org SEVERAL SINGLE AGENTS have been identified for the control of chemotherapy- induced nausea
and emesis. Drugs evaluated in controlled trials include the phenothiazines,'
metoclopramide,24 haloperidol,7 the cannabi- noids,8 9 and dexamethasone.'0-' Further ... Cited by 203 - Related articles - All 5 versions
M Tonato, F Roila, AD Favero - Annals of Oncology, 1991 - Eur Soc Med Oncology Summary. Chemotherapy-related nausea and vomiting can be controlled with available antiemetics
in a high per- centage of patients, while emesis remains a critical problem in some subgroups
and with certain drugs. In the ceaseless attempt to find newer drugs and better treatment ... Cited by 74 - Related articles - All 2 versions
- ►ascopubs.org [PDF] J Bonneterre, B Chevallier, R Metz, P Fargeot, … - Journal of Clinical …, 1990 - jco.ascopubs.org PATIENTS who receive cyclophosphamide and fluorouracil in combination with doxo- rubicin
(FAC) or epirubicin (FEC) for breast cancer (70% to 100%) frequently experience nausea and
vomiting.1,2 High-dose metoclopra- mide (2 mg/kg intravenously [IV], 2-hourly) has been ... Cited by 67 - Related articles - All 5 versions
